about
Clinical application of CpG-, non-CpG-, and antisense oligodeoxynucleotides as immunomodulatorsAdeno-associated virus vector integrationProgress toward therapy with antisense-mediated splicing modulationTechnology evaluation: gene therapy (FGF-5), VicalShotgun proteomics: tools for the analysis of complex biological systemsReslizumab, a humanized anti-IL-5 mAb for the treatment of eosinophil-mediated inflammatory conditionsDrug evaluation: tefibazumab--a monoclonal antibody against staphylococcal infectionTRU-015, a fusion protein derived from an anti-CD20 antibody, for the treatment of rheumatoid arthritisTranscriptional gene silencing through epigenetic changes mediated by non-coding RNAsThe ATCG of drug discovery.Progress on baculovirus-derived influenza vaccines.GSK's novel split-virus adjuvanted vaccines for the prevention of the H5N1 strain of avian influenza infection.Developing cell culture-derived pandemic vaccines.Gene therapy from the perspective of systems biology.Untapped resources for pharmacogenomic discovery in psychiatry.Large-scale open bioinformatics data resources.A human protein atlas based on antibody proteomics.Triplex-forming molecules for modulation of DNA information processing.Aptamers: selected oligonucleotides for therapy.Peptide mimotopes as candidate vaccines.DNA shuffling and vaccines.Phage as gene delivery vectors.Integrin-mediated vectors for gene transfer and therapy.RNA interference for the identification of disease-associated genes.Enabling parallel protein analysis through mass spectrometry.Selective gene regulation with designed transcription factors: implications for therapy.Affordable proteomics: the two-hybrid systems.Technology evaluation: SAGE, Genzyme molecular oncology.Drug discovery, drug development and the emerging world of pharmacogenomics: prospecting for information in a data-rich landscape.Recent advances in oncoproteomics.Web alert. Molecular vaccines for disease prevention and therapy.Serum protein fingerprinting.Development of novel vaccines using DNA shuffling and screening strategies.1D09C3, an mAb specific for MHC-II.Technology evaluation: thrombopoietin, Genentech/Pharmacia & Upjohn.Toward antisense oligonucleotide therapy for cancer: ISIS compounds in clinical development.Veltuzumab, an anti-CD20 mAb for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia and immune thrombocytopenic purpura.Rozrolimupab, symphobodies against rhesus D, for the potential prevention of hemolytic disease of the newborn and the treatment of idiopathic thrombocytopenic purpura.Aptamers as molecular tools for bioanalytical methods.Peptoids as potential therapeutics.
P1433
Q24498504-DBCAAE57-789D-4F92-9B49-C7AFF34DD695Q24624120-BE374F8B-796A-4BFB-9BCF-E7A2AB0FA2FFQ27489807-4F27A5A5-95B7-4B26-8640-37DD7F766819Q28206368-760913CC-613C-4872-AEB3-8B744EB3EAE8Q28215896-E677FC77-DD70-435A-84BC-98EC6F1E72ADQ28246755-B06B2E3F-AC13-41C7-8A85-C9FAD91BC3A5Q28271519-B82C5DDC-A075-4968-9C66-6C175052CD72Q28272698-CE6A34F7-4436-4E0F-B38E-15D79E27D037Q28278927-630AA2D0-B370-480B-9B5B-84FF149345B3Q30327987-EFA616B5-CA64-4B05-9F05-3251534476B3Q30367431-BEB5B231-DBF3-42E6-960A-4AD3B2AA2B6AQ30377667-5B0C6492-8436-45DF-993E-43E0BF1D0D72Q30385466-511B80A7-FAC4-444B-8CBB-5125EFB999E0Q30430438-03FB7CDC-D56A-4A43-8017-399F6809EC3EQ30444388-4369C590-6485-4076-B90B-05B99F85043EQ30482364-02722266-FD83-48D5-B170-3626BFFDA938Q30483120-26C0A3F8-5BFC-4DAD-B7A9-DFD8CC2D502EQ30658608-502BDE3E-4EF4-416B-ACC4-ECB4F7388A1BQ30658614-C9D809A6-E76F-448D-9385-9E6DF1D15A32Q30658620-35D15B97-FA0C-4C08-8CFF-28A3198F2E2DQ30658627-EA084EDF-3088-4222-9626-D385B51160E8Q30667387-13BB098C-E560-4E70-8987-02A98C2D528CQ30765544-D972958C-EF8B-4B8F-900C-36DA7B0921BDQ31078970-AB5ACBDB-D74B-49F4-B0FC-6E022C7861F9Q31132292-D683A0C6-E201-4C8C-8015-5ADFEB03BBBBQ31143725-932D4466-C5BA-43B7-8A6C-B6D32722758DQ31149993-29A3708B-4916-4FE6-8D18-3A4E2E28F7FFQ31880491-E7B91E6D-0DFD-4359-8697-F4DD29879766Q31880507-B7A1277F-8226-4CC7-9431-47B32B3E8CF6Q32167457-49A46135-D8D5-4BAD-BE6C-9F324622B171Q33181785-ED9DE2D1-1EE6-40C6-8ABF-E51281891936Q33197307-74F8D414-C7C0-4CB8-84DC-6C3FCC59A3BFQ33199222-4104D82F-A866-4A53-9C59-D2AD6B209EA5Q33316942-7621A893-C316-473B-8587-375CC31328D4Q33336365-800A9690-BF30-4B2A-AF25-B95AB76DF582Q33339859-891FBD89-C8C8-4AB4-831B-74F57C1F69BEQ33383933-48C590E6-8671-4C80-8E2D-6F56451D331EQ33393274-4BF65D48-4BB8-4F3D-8C70-FED07070BA64Q33423943-31E1BF09-A685-40F8-9F29-6E789E441FEDQ33455976-12307809-1951-44B4-A27E-D696002F82C6
P1433
description
czasopismo naukowe
@pl
journal
@en
revista científica
@es
rivista scientifica
@it
vědecký časopis
@cs
wetenschappelijk tijdschrift
@nl
wissenschaftliche Fachzeitschrift
@de
مجلة
@ar
name
Current Opinion in Molecular Therapeutics
@ast
Current Opinion in Molecular Therapeutics
@da
Current Opinion in Molecular Therapeutics
@en
Current Opinion in Molecular Therapeutics
@es
Current Opinion in Molecular Therapeutics
@fi
Current Opinion in Molecular Therapeutics
@fr
Current Opinion in Molecular Therapeutics
@it
Current Opinion in Molecular Therapeutics
@nb
Current Opinion in Molecular Therapeutics
@nl
Current Opinion in Molecular Therapeutics
@nn
type
label
Current Opinion in Molecular Therapeutics
@ast
Current Opinion in Molecular Therapeutics
@da
Current Opinion in Molecular Therapeutics
@en
Current Opinion in Molecular Therapeutics
@es
Current Opinion in Molecular Therapeutics
@fi
Current Opinion in Molecular Therapeutics
@fr
Current Opinion in Molecular Therapeutics
@it
Current Opinion in Molecular Therapeutics
@nb
Current Opinion in Molecular Therapeutics
@nl
Current Opinion in Molecular Therapeutics
@nn
prefLabel
Current Opinion in Molecular Therapeutics
@ast
Current Opinion in Molecular Therapeutics
@da
Current Opinion in Molecular Therapeutics
@en
Current Opinion in Molecular Therapeutics
@es
Current Opinion in Molecular Therapeutics
@fi
Current Opinion in Molecular Therapeutics
@fr
Current Opinion in Molecular Therapeutics
@it
Current Opinion in Molecular Therapeutics
@nb
Current Opinion in Molecular Therapeutics
@nl
Current Opinion in Molecular Therapeutics
@nn
P1055
P1058
P1156
P1250
P1277
P1476
Current Opinion in Molecular Therapeutics
@und